West Pharmaceutical Services Beheer
Beheer criteriumcontroles 4/4
De CEO West Pharmaceutical Services is Eric Green, benoemd in Apr2015, heeft een ambtstermijn van 9.58 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 9.40M, bestaande uit 12.1% salaris en 87.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.23% van de aandelen van het bedrijf, ter waarde $ 51.06M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.5 jaar en 9.5 jaar.
Belangrijke informatie
Eric Green
Algemeen directeur
US$9.4m
Totale compensatie
| Percentage CEO-salaris | 12.1% |
| Dienstverband CEO | 9.6yrs |
| Eigendom CEO | 0.2% |
| Management gemiddelde ambtstermijn | 4.5yrs |
| Gemiddelde ambtstermijn bestuur | 9.5yrs |
Recente managementupdates
Recent updates
Should You Think About Buying West Pharmaceutical Services, Inc. (NYSE:WST) Now?
Nov 15
West Pharmaceutical Services, Inc. Just Recorded A 27% EPS Beat: Here's What Analysts Are Forecasting Next
Oct 27West Pharma's Destocking Dilemma: Why Staying On The Sidelines Makes Sense
Oct 11Getting In Cheap On West Pharmaceutical Services, Inc. (NYSE:WST) Is Unlikely
Sep 20A Look At The Intrinsic Value Of West Pharmaceutical Services, Inc. (NYSE:WST)
Sep 02West Pharmaceutical Services, Inc. Just Missed Earnings - But Analysts Have Updated Their Models
Jul 28West Pharmaceutical: Continued Destocking And A High Valuation Post Q2 Results (Rating Maintained)
Jul 25Is It Time To Consider Buying West Pharmaceutical Services, Inc. (NYSE:WST)?
Jul 15We Think West Pharmaceutical Services (NYSE:WST) Can Stay On Top Of Its Debt
Jun 27Estimating The Fair Value Of West Pharmaceutical Services, Inc. (NYSE:WST)
May 21West Pharmaceutical: Pick And Shovels Of The Injectable Drug Industry
May 11West Pharmaceutical Services, Inc.'s (NYSE:WST) Business Is Yet to Catch Up With Its Share Price
Mar 30Is West Pharmaceutical Services (NYSE:WST) A Risky Investment?
Mar 12Why West Pharma Is Far From Done
Feb 28West Pharmaceutical Services, Inc.'s (NYSE:WST) Intrinsic Value Is Potentially 19% Below Its Share Price
Feb 20West Pharmaceutical Services: Still Too Expensive After The Recent Drop
Feb 20What Does West Pharmaceutical Services, Inc.'s (NYSE:WST) Share Price Indicate?
Jan 10West Pharmaceutical: Great Business, Not So Great Valuation
Jan 08What West Pharmaceutical Services, Inc.'s (NYSE:WST) P/E Is Not Telling You
Dec 18West Pharmaceutical Services (NYSE:WST) Has A Pretty Healthy Balance Sheet
Nov 27West Pharmaceutical Services: The Run Might Be Over
Oct 18Is West Pharmaceutical Services, Inc. (NYSE:WST) Potentially Undervalued?
Sep 24Is West Pharmaceutical Services (NYSE:WST) Using Too Much Debt?
Aug 22West Pharmaceutical: Revise To Buy On Exceptional Economic Characteristics
Aug 08What Is West Pharmaceutical Services, Inc.'s (NYSE:WST) Share Price Doing?
Jun 26West Pharmaceutical: Hard To Justify The Price
May 26Is West Pharmaceutical Services (NYSE:WST) Using Too Much Debt?
May 16At US$330, Is It Time To Put West Pharmaceutical Services, Inc. (NYSE:WST) On Your Watch List?
Mar 20West Pharmaceutical Services' (NYSE:WST) Soft Earnings Don't Show The Whole Picture
Feb 28West Pharmaceutical Q4 2022 Earnings Preview
Feb 15West Pharmaceutical Services (NYSE:WST) Has A Pretty Healthy Balance Sheet
Jan 31West Pharmaceutical: An Earnings Decline Seen In 2023, Shares Still Appear Expensive
Dec 19West Pharmaceutical declares $0.19 dividend
Dec 13Why West Pharmaceutical Services, Inc. (NYSE:WST) Could Be Worth Watching
Nov 29Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$500m |
| Jun 30 2024 | n/a | n/a | US$525m |
| Mar 31 2024 | n/a | n/a | US$569m |
| Dec 31 2023 | US$9m | US$1m | US$593m |
| Sep 30 2023 | n/a | n/a | US$559m |
| Jun 30 2023 | n/a | n/a | US$519m |
| Mar 31 2023 | n/a | n/a | US$552m |
| Dec 31 2022 | US$8m | US$1m | US$586m |
| Sep 30 2022 | n/a | n/a | US$631m |
| Jun 30 2022 | n/a | n/a | US$686m |
| Mar 31 2022 | n/a | n/a | US$684m |
| Dec 31 2021 | US$9m | US$1m | US$662m |
| Sep 30 2021 | n/a | n/a | US$613m |
| Jun 30 2021 | n/a | n/a | US$519m |
| Mar 31 2021 | n/a | n/a | US$423m |
| Dec 31 2020 | US$8m | US$989k | US$346m |
| Sep 30 2020 | n/a | n/a | US$312m |
| Jun 30 2020 | n/a | n/a | US$286m |
| Mar 31 2020 | n/a | n/a | US$261m |
| Dec 31 2019 | US$7m | US$936k | US$242m |
| Sep 30 2019 | n/a | n/a | US$230m |
| Jun 30 2019 | n/a | n/a | US$229m |
| Mar 31 2019 | n/a | n/a | US$219m |
| Dec 31 2018 | US$5m | US$880k | US$207m |
| Sep 30 2018 | n/a | n/a | US$155m |
| Jun 30 2018 | n/a | n/a | US$151m |
| Mar 31 2018 | n/a | n/a | US$133m |
| Dec 31 2017 | US$5m | US$824k | US$151m |
Compensatie versus markt: De totale vergoeding ($USD 9.40M ) Eric } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 12.73M ).
Compensatie versus inkomsten: De vergoeding van Eric is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Eric Green (54 yo)
9.6yrs
Tenure
US$9,395,896
Compensatie
Mr. Eric M. Green serves as Independent Director at Ecolab Inc. since December 08, 2022. He has been the Chief Executive Officer of West Pharmaceutical Services, Inc. since April 24, 2015 and its President...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Non-Independent Chair of the Board | 9.6yrs | US$9.40m | 0.23% $ 51.1m | |
| Senior VP & CFO | 6.4yrs | US$3.64m | 0.0095% $ 2.1m | |
| Senior VP & CTO | 3.9yrs | US$1.67m | 0.0043% $ 953.6k | |
| Senior VP | 3.9yrs | US$1.49m | 0.0019% $ 414.0k | |
| Senior VP & Chief Commercial Officer | 5yrs | US$1.53m | 0.0067% $ 1.5m | |
| VP, Chief Accounting Officer & Corporate Controller | 5.1yrs | geen gegevens | 0.0018% $ 398.6k | |
| Head of Investor Relations | no data | geen gegevens | geen gegevens | |
| Vice President of Global Communications | no data | geen gegevens | geen gegevens | |
| Senior VP of Strategy & Corporate Development | less than a year | geen gegevens | geen gegevens | |
| Chief Human Resources Officer & Senior VP | 9.1yrs | US$1.14m | 0.0090% $ 2.0m | |
| Senior VP and Chief Quality & Regulatory Officer | 2.5yrs | geen gegevens | geen gegevens | |
| President of Contract Manufacturing | less than a year | geen gegevens | geen gegevens |
4.5yrs
Gemiddelde duur
54yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van WST wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.5 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Non-Independent Chair of the Board | 9.5yrs | US$9.40m | 0.23% $ 51.1m | |
| Independent Director | 10.8yrs | US$359.35k | 0.024% $ 5.2m | |
| Independent Director | 4.8yrs | US$330.66k | 0.0034% $ 740.0k | |
| Independent Director | 17.1yrs | US$390.35k | 0.059% $ 13.1m | |
| Independent Director | 13.8yrs | US$378.23k | 0.056% $ 12.3m | |
| Independent Director | 13.8yrs | US$377.01k | 0.059% $ 13.1m | |
| Lead Independent Director | 8.2yrs | US$367.44k | 0.012% $ 2.6m | |
| Independent Director | 2.3yrs | US$331.46k | 0.0015% $ 325.9k | |
| Independent Director | 12.8yrs | US$362.83k | 0.040% $ 8.9m | |
| Independent Director | 7.4yrs | US$333.45k | geen gegevens | |
| Honorary Director | no data | geen gegevens | geen gegevens | |
| Independent Director | 3.3yrs | US$321.43k | 0.00087% $ 191.6k |
9.5yrs
Gemiddelde duur
63yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van WST wordt beschouwd als ervaren (gemiddelde ambtstermijn 9.5 jaar).